Nivolumab

  • PDF / 169,785 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 110 Downloads / 166 Views

DOWNLOAD

REPORT


1 S

Thyroid dysfunctions: 3 case reports In a study of 11 patients conducted between 28 June 2018 and 15 January 2019 at a hospital, 3 patients [ages not stated; not all sexes stated] were described, who developed hyperthyroidism or hypothyroidism during treatment with nivolumab for non-small cell lung cancer [duration of treatments to reactions onsets not stated; not all outcomes stated]. Patient 1: The patient, who had non-small cell lung cancer (NSCLC), received IV nivolumab 240mg every 2 weeks. Six weeks after starting nivolumab therapy (3 cycles later), the patient developed grade 2 hyperthyroidism. The patient received treatment with thiamazole [methimazole] for hyperthyroidism and it lasted for 6 weeks. However, the patient suffered from hypothyroidism and received treatment with levothyroxine sodium [levothyroxine]. The patient received Nivolumab until grade 3 immune-related hepatic adverse event occurred after 7 cycles of initiation nivolumab. At the time of this report hypothyroidism did not recover and lasted for 15 weeks. Patient 2: The woman, who had NSCLC, received IV nivolumab 240mg every 2 weeks. Twelve weeks after starting nivolumab therapy (5 cycles later), she developed grade 2 hypothyroidism. Therefore, she received treatment with levothyroxine sodium. Her hypothyroidism lasted for 5 weeks. Treatment with levothyroxine sodium was not stopped. Patient 3: The man, who had NSCLC, received IV nivolumab 240mg every 2 weeks. Six weeks after starting nivolumab therapy (3 cycles later), he developed asymptomatic grade 1 hyperthyroidism which lasted for 4 weeks. Two weeks after recovery of hyperthyroidism, he developed asymptomatic grade 1 hypothyroidism which lasted for 14 weeks. Zhang X, et al. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer. Interdisciplinary Sciences: Computational Life Sciences 11: 287-291, 11 Jun 2019. Available from: URL: http://doi.org/10.1007/s12539-019-00337-8 803445468

0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 18 Jan 2020 No. 1787